[{"id":"5455e56f-c7d0-43e1-93b2-556c1632eeb2","acronym":"UCLA l-08","url":"https://clinicaltrials.gov/study/NCT04285671","created_at":"2023-11-26T01:10:15.098Z","updated_at":"2024-07-02T16:34:26.639Z","phase":"Phase 1/2","brief_title":"Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04285671 - UCLA l-08","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" HER-2 • AXL","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["HER-2 • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp) • Portrazza (necitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/29/2021","start_date":" 01/29/2021","primary_txt":" Primary completion: 12/02/2025","primary_completion_date":" 12/02/2025","study_txt":" Completion: 12/02/2026","study_completion_date":" 12/02/2026","last_update_posted":"2024-06-13"},{"id":"839f620b-12d4-4a91-a1bc-669aefdc71c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02496663","created_at":"2024-03-06T21:31:26.529Z","updated_at":"2024-07-02T16:34:58.872Z","phase":"Phase 1","brief_title":"Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor","source_id_and_acronym":"NCT02496663","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Portrazza (necitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 05/11/2016","start_date":" 05/11/2016","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"11abb3b6-ef21-46f0-b0b1-830af73de8a4","acronym":"SQUIRE","url":"https://clinicaltrials.gov/study/NCT00981058","created_at":"2021-01-18T03:49:41.003Z","updated_at":"2024-07-02T16:35:13.881Z","phase":"Phase 3","brief_title":"First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin","source_id_and_acronym":"NCT00981058 - SQUIRE","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR • KRAS","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • EGFR mutation + KRAS mutation","tags":["EGFR • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • EGFR mutation + KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Portrazza (necitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1093","initiation":"Initiation: 01/07/2010","start_date":" 01/07/2010","primary_txt":" Primary completion: 06/17/2013","primary_completion_date":" 06/17/2013","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-03-20"},{"id":"d46752a6-da4d-4aed-81ab-001303ea2341","acronym":"","url":"https://clinicaltrials.gov/study/NCT02789345","created_at":"2021-01-17T17:40:28.463Z","updated_at":"2025-02-25T15:07:01.633Z","phase":"Phase 1","brief_title":"A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer","source_id_and_acronym":"NCT02789345","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Cyramza (ramucirumab) • Portrazza (necitumumab)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 10/24/2016","start_date":" 10/24/2016","primary_txt":" Primary completion: 10/19/2017","primary_completion_date":" 10/19/2017","study_txt":" Completion: 05/09/2022","study_completion_date":" 05/09/2022","last_update_posted":"2024-02-05"},{"id":"5e2cc56d-4489-4e68-97aa-77f57a03e29e","acronym":"INSPIRE","url":"https://clinicaltrials.gov/study/NCT00982111","created_at":"2021-01-18T03:49:55.624Z","updated_at":"2024-07-02T16:36:18.612Z","phase":"Phase 3","brief_title":"First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin","source_id_and_acronym":"NCT00982111 - INSPIRE","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR overexpression • EGFR underexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR overexpression • EGFR underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed • Portrazza (necitumumab)"],"overall_status":"Completed","enrollment":" Enrollment 633","initiation":"Initiation: 11/02/2009","start_date":" 11/02/2009","primary_txt":" Primary completion: 11/14/2012","primary_completion_date":" 11/14/2012","study_txt":" Completion: 12/23/2020","study_completion_date":" 12/23/2020","last_update_posted":"2022-01-11"},{"id":"8bbfa806-c276-4eb4-85a2-10cf96b65ccd","acronym":"","url":"https://clinicaltrials.gov/study/NCT02411591","created_at":"2021-01-18T11:31:12.553Z","updated_at":"2024-07-02T16:36:43.428Z","phase":"Phase 1b","brief_title":"A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT02411591","lead_sponsor":"Eli Lilly and Company","biomarkers":" ALK","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Portrazza (necitumumab)"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 06/04/2015","start_date":" 06/04/2015","primary_txt":" Primary completion: 06/23/2017","primary_completion_date":" 06/23/2017","study_txt":" Completion: 05/28/2019","study_completion_date":" 05/28/2019","last_update_posted":"2020-07-09"},{"id":"ba6f34a6-8973-49b0-a6a0-cee60868909c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01763788","created_at":"2021-01-18T07:45:14.839Z","updated_at":"2024-07-02T16:36:54.245Z","phase":"Phase 1b/2","brief_title":"A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT01763788","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Portrazza (necitumumab)"],"overall_status":"Completed","enrollment":" Enrollment 192","initiation":"Initiation: 05/07/2013","start_date":" 05/07/2013","primary_txt":" Primary completion: 06/28/2017","primary_completion_date":" 06/28/2017","study_txt":" Completion: 10/17/2018","study_completion_date":" 10/17/2018","last_update_posted":"2019-10-25"},{"id":"6b46e660-8bcb-40e3-8143-dc61b1789d73","acronym":"","url":"https://clinicaltrials.gov/study/NCT01606748","created_at":"2021-01-18T06:52:28.754Z","updated_at":"2024-07-02T16:36:55.102Z","phase":"Phase 2","brief_title":"A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin","source_id_and_acronym":"NCT01606748","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Portrazza (necitumumab)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 06/01/2013","primary_completion_date":" 06/01/2013","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2019-09-30"},{"id":"f29dca46-1e38-4071-974e-adcc8daa9f0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02941601","created_at":"2021-01-18T14:26:35.822Z","updated_at":"2024-07-02T16:36:55.120Z","phase":"Phase 2","brief_title":"A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT02941601","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • Portrazza (necitumumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 02/01/2019","study_completion_date":" 02/01/2019","last_update_posted":"2019-09-27"},{"id":"212dc421-1578-4213-8fbd-ae844312e168","acronym":"","url":"https://clinicaltrials.gov/study/NCT01769391","created_at":"2021-01-18T07:47:36.729Z","updated_at":"2024-07-02T16:36:55.391Z","phase":"Phase 2","brief_title":"A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01769391","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Portrazza (necitumumab)"],"overall_status":"Completed","enrollment":" Enrollment 167","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 07/01/2017","study_completion_date":" 07/01/2017","last_update_posted":"2019-09-20"},{"id":"26155faf-c654-41c2-b01a-0d5c3e9955f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01624467","created_at":"2021-01-18T06:58:12.193Z","updated_at":"2024-07-02T16:37:30.283Z","phase":"Phase 2","brief_title":"A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors","source_id_and_acronym":"NCT01624467","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Portrazza (necitumumab)"],"overall_status":"Completed","enrollment":" Enrollment 75","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 05/01/2014","primary_completion_date":" 05/01/2014","study_txt":" Completion: 06/01/2015","study_completion_date":" 06/01/2015","last_update_posted":"2016-07-25"}]